

Press Release

NutrigeneAI Showcases Breakthrough Innovation at Geneva International Exhibition of Inventions

Hong Kong | 15th Mar 2026

NutrigeneAI Biotech Limited is proud to have participated in the 51st International Exhibition of Inventions Geneva as part of the delegation from The Chinese University of Hong Kong (CUHK), contributing to the university's outstanding achievements on the global stage.

During the exhibition, NutrigeneAI, as a CUHK startup, presented one of its key innovations developed under the leadership of Prof. Jack Wong and his research team. The showcased technology features the world's first-in-class intramuscular injectable iPSC-derived cell therapeutic drug, designed to regenerate blood vessels and improve microcirculation.

This novel, non-invasive therapeutic approach targets patients suffering from diabetic foot and peripheral artery disease (PAD), with the aim of reducing the risk of amputation through the repair of damaged vascular tissues. The innovation highlights NutrigeneAI's commitment to translating advanced biomedical research into impactful clinical solutions.

The exhibition, recognised as one of the world's most prestigious platforms for innovation, gathered over 1,000 inventions from more than 40 countries and regions. NutrigeneAI's participation reflects its growing role within the global biotechnology ecosystem and its close collaboration with CUHK in advancing cutting-edge research.

NutrigeneAI remains dedicated to driving innovation at the intersection of biotechnology, AI, and precision health, and will continue to explore new opportunities to bring transformative healthcare solutions to patients worldwide.